Cel
Though survival of children with acute lymphoblastic leukaemia (ALL) has improved, relapse remains a leading cause of mortality in childhood cancer. Given the rarity of the disease, only a large international cooperative group can recruit sufficient patients for prospective studies with specific questions in biologic subgroups. Under the umbrella of the I-BFM SG all relevant mainly European study groups are creating the worldwide largest Study for Children with Relapsed ALL (IntReALL 2010). The aim is to develop optimized standard treatment as platform for systematic randomized phase II and III studies on the most promising new and targeted agents. An adequate trial structure, an optimized web based database, and standardized diagnostic methods need to be established.
Patients are stratified into a standard (SR) and a high risk (HR) group according to established factors. For SR patients, the best available treatment protocols ALL-REZ BFM 2002 and ALL R3 are randomly compared, and the additional effect on survival of the humanized monoclonal CD22 directed antibody epratuzumab is investigated. HR patients who have unsatisfying remission rates will receive an intensified induction with the proteasome inhibitor bortezomib randomly combined with standard induction therapy. IntReALL 2010 allows for comprehensive tumour banking and systematic biologic research in subgroups with correlation to clinical outcome. SMEs will be involved into project management, data base development, and pharmaceutical and biotechnological research to ensure innovation in the respective areas. IntReALL 2010 is embedded in a network of European academic structures relevant for childhood cancer. It will be a cornerstone of drug development in childhood leukaemia and the only trial with the potential for well powered phase III studies in this indication. IntReALL 2010 will harmonize ALL-relapse therapy, establish highest diagnostic and therapeutic standard and improve survival of children with ALL.
Dziedzina nauki
Zaproszenie do składania wniosków
FP7-HEALTH-2011-two-stage
Zobacz inne projekty w ramach tego zaproszenia
System finansowania
CP-FP - Small or medium-scale focused research projectKoordynator
10117 Berlin
Niemcy
Zobacz na mapie
Uczestnicy (28)
8006 Zurich
Zobacz na mapie
150 06 Praha 5
Zobacz na mapie
1090 Wien
Zobacz na mapie
Zakończenie uczestnictwa
25030 BESANCON CEDEX
Zobacz na mapie
1099 023 Lisboa
Zobacz na mapie
1020 BRUXELLES
Zobacz na mapie
17177 Stockholm
Zobacz na mapie
3400 Hillerod
Zobacz na mapie
20520 Turku
Zobacz na mapie
0450 Oslo
Zobacz na mapie
M13 9PL Manchester
Zobacz na mapie
Zakończenie uczestnictwa
6525 XZ Nijmegen
Zobacz na mapie
00165 Roma
Zobacz na mapie
64239 Tel Aviv
Zobacz na mapie
50 367 Wroclaw
Zobacz na mapie
Zakończenie uczestnictwa
46015 VALENCIA
Zobacz na mapie
1018 RG Amsterdam
Zobacz na mapie
OX1 2JD Oxford
Zobacz na mapie
30625 Hannover
Zobacz na mapie
07950 Morris Plains
Zobacz na mapie
80335 MUNCHEN
Zobacz na mapie
Zakończenie uczestnictwa
CB22 3AT CAMBRIDGE
Zobacz na mapie
10117 BERLIN
Zobacz na mapie
1200 Bruxelles / Brussel
Zobacz na mapie
Zakończenie uczestnictwa
2333 BZ LEIDEN
Zobacz na mapie
06003 Nice
Zobacz na mapie
3584CS Utrecht
Zobacz na mapie
2333 BZ Leiden
Zobacz na mapie